American Lung Association - Request for Extension

The American Lung Association commends the Food and Drug Administration for including lung cancer in the Patient-Focused Drug Development Initiative. The June 28 meeting and public comment period are important opportunities for lung cancer patients to share their perspective with the FDA. Our organization is deeply committed to lung cancer patients and their families, and to better cures and treatments for lung cancer. FDA has asked a series of important and detailed questions. I am writing today to request that you provide more time for patients and other stakeholders to submit meaningful comments following this meeting. While we deeply appreciate FDA’s aggressive timeline recognizes the urgency of lung cancer, additional time is needed in order for patients to prepare thorough and thoughtful comments and to respond to the important issues that undoubtedly will be raised at the June 28 meeting. Therefore, the American Lung Association respectfully requests that FDA provide a 30-day extension of the comment period on Docket No. FDA-2013-N-0596, until August 28, 2013.